Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 93

Similar articles for PubMed (Select 21979579)

1.

Retargeting NK92 cells using an HLA-A2-restricted, EBNA3C-specific chimeric antigen receptor.

Tassev DV, Cheng M, Cheung NK.

Cancer Gene Ther. 2012 Feb;19(2):84-100. doi: 10.1038/cgt.2011.66. Epub 2011 Oct 7.

PMID:
21979579
3.
5.
7.

Impact of antigen presentation on TCR modulation and cytokine release: implications for detection and sorting of antigen-specific CD8+ T cells using HLA-A2 wild-type or HLA-A2 mutant tetrameric complexes.

Jäger E, Salter R, Castelli C, Höhn H, Freitag K, Karbach J, Neukirch C, Necker A, Knuth A, Maeurer MJ.

J Immunol. 2002 Mar 15;168(6):2766-72.

8.

Tax and M1 peptide/HLA-A2-specific Fabs and T cell receptors recognize nonidentical structural features on peptide/HLA-A2 complexes.

Biddison WE, Turner RV, Gagnon SJ, Lev A, Cohen CJ, Reiter Y.

J Immunol. 2003 Sep 15;171(6):3064-74.

9.

Hsp70-like protein 1 fusion protein enhances induction of carcinoembryonic antigen-specific CD8+ CTL response by dendritic cell vaccine.

Wu Y, Wan T, Zhou X, Wang B, Yang F, Li N, Chen G, Dai S, Liu S, Zhang M, Cao X.

Cancer Res. 2005 Jun 1;65(11):4947-54.

10.

Peptides derived from human insulin-like growth factor-II mRNA binding protein 3 can induce human leukocyte antigen-A2-restricted cytotoxic T lymphocytes reactive to cancer cells.

Tomita Y, Harao M, Senju S, Imai K, Hirata S, Irie A, Inoue M, Hayashida Y, Yoshimoto K, Shiraishi K, Mori T, Nomori H, Kohrogi H, Nishimura Y.

Cancer Sci. 2011 Jan;102(1):71-8. doi: 10.1111/j.1349-7006.2010.01780.x. Epub 2010 Nov 19.

PMID:
21087352
11.

Characterization of an human leucocyte antigen A2-restricted Epstein-Barr virus nuclear antigen-1-derived cytotoxic T-lymphocyte epitope.

Marescotti D, Destro F, Baldisserotto A, Marastoni M, Coppotelli G, Masucci M, Gavioli R.

Immunology. 2010 Mar;129(3):386-95. doi: 10.1111/j.1365-2567.2009.03190.x. Epub 2009 Nov 16.

12.

Specific targeting of a naturally presented osteosarcoma antigen, papillomavirus binding factor peptide, using an artificial monoclonal antibody.

Tsukahara T, Emori M, Murata K, Hirano T, Muroi N, Kyono M, Toji S, Watanabe K, Torigoe T, Kochin V, Asanuma H, Matsumiya H, Yamashita K, Himi T, Ichimiya S, Wada T, Yamashita T, Hasegawa T, Sato N.

J Biol Chem. 2014 Aug 8;289(32):22035-47. doi: 10.1074/jbc.M114.568725. Epub 2014 Jun 24.

PMID:
24962571
13.
14.

Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen.

Terasawa H, Tsang KY, Gulley J, Arlen P, Schlom J.

Clin Cancer Res. 2002 Jan;8(1):41-53.

15.

A novel HLA-A2-restricted CTL epitope of tumor-associated antigen L6 can inhibit tumor growth in vivo.

Tu SH, Huang HI, Lin SI, Liu HY, Sher YP, Chiang SK, Chong P, Roffler S, Tseng GC, Chen HW, Liu SJ.

J Immunother. 2012 Apr;35(3):235-44. doi: 10.1097/CJI.0b013e318248f2ae.

PMID:
22421941
16.

Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine.

Tsang KY, Zaremba S, Nieroda CA, Zhu MZ, Hamilton JM, Schlom J.

J Natl Cancer Inst. 1995 Jul 5;87(13):982-90.

PMID:
7629885
18.

HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2.

Lee SP, Thomas WA, Murray RJ, Khanim F, Kaur S, Young LS, Rowe M, Kurilla M, Rickinson AB.

J Virol. 1993 Dec;67(12):7428-35.

19.

Epitope-enhanced conserved HIV-1 peptide protects HLA-A2-transgenic mice against virus expressing HIV-1 antigen.

Okazaki T, Pendleton CD, Lemonnier F, Berzofsky JA.

J Immunol. 2003 Sep 1;171(5):2548-55.

20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk